1.Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 2007; 21:929-942.
2.Lutzky V, Hannawi S, Thomas R. Cells of the synovium in rheumatoid arthritis. Dendritic cells. Arthritis Res Ther 2007: 9:219.
3.Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005; 11:S39-44.
4.Panayi GS, Corrigall VM. BiP, an anti-inflammatory ER protein, is a potential new therapy for the treatment of rheumatoid arthritis. Novartis Found Symp 2008; 291:212-216.
5.Yamaoka K, Tanaka Y. Jak inhibitor; possibility and mechanism as a new disease modifying anti-rheumatic drug. Nihon Rinsho Meneki Gakkai Kaishi 2009; 32:85-91.
6.Rossi M,Young JW.Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005; 175:1373-1381.
7.Steinbrink K, Mahnke K, Grabbe S, Enk AH, Jonuleit H. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? Hum Immunol 2009; 70:289-293.
8.Thomson AW, Robbins PD. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann Rheum Dis 2008; 67:iii90-96.
9.Manfred B, Lutz GS. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23:445-451.
10.Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7:610-621.
11.Taub DD. Neuroendocrine interactions in the immune system. Cell Immunol 2008; 252:1-6.
12.Wang H, Xing L, Li W, Hou L, Guo J, Wang X. Production and secretion of calcitonin gene-related peptide from human lymphocytes. J Neuroimmunol 2002; 130:155-162.
13.Harzenetter, MD, Novotny AR, Gais P, Molina CA, Altmayr F, Holzmann B. Negative regulation of TLR responses by the neuropeptide CGRP is mediated by the transcriptional repressor ICER. J Immunol 2007; 179:607-615.
14.Gomes RN, Castro-Faria-Neto HC, Bozza PT, Soares MB, Shoemaker CB, David JR, et al. Calcitonin gene- related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia. Shock 2005; 24:590-594.
15.Bracci-Laudiero L, Aloe L, Buanne P, Finn A, Stenfors C, Vigneti E, et al. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? J Neuroimmunol 2002; 123:58-65.
16.Fox FE, Kubin M, Cassin M, Niu Z, Hosoi J, Torii H, et al. Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J Invest Dermatol 1997; 108:43-48.
17.Torii H, Hosoi J, Beissert S, Xu S, Fox FE, Asahina A, et al. Regulation of cytokine expression in macrophages and the Langerhans cell-like line XS52 by calcitonin gene-related peptide. J Leukoc Biol 1997; 61:216-223.
18.Reyes-Garcia MG, Garcia-Tamayo F. A neurotransmitter system that regulates macrophage pro-inflammatory functions. J Neuroimmunol 2009; 216:20-30.
19.Carucci JA, Ignatius R, Wei Y, Cypess AM, Schaer DA, Pope M, et al. Calcitonin gene-related peptide decreases expression of HLA-DR and CD86 by human dendritic cells and dampens dendritic cell-driven T cell- proliferative responses via the type I calcitonin gene-related peptide receptor. J Immunol 2000; 164:3494-3499.
20.Seiffert K, Granstein RD. Neuroendocrine regulation of skin dendritic cells. Ann N Y Acad Sci 2006; 1088:195-206.
21.Bulloch K,McEwen BS, Nordberg J, Diwa A, Baird S. Selective regulation of T-cell development and function by calcitonin gene-related peptide in thymus and spleen. An example of differential regional regulation of immunity by the neuroendocrine system. Ann N Y Acad Sci 1998; 840:551-62.
22.Talme T, Liu Z, Sundqvist KG. The neuropeptide calcitonin gene-related peptide (CGRP) stimulates T cell migration into collagen matrices. J Neuroimmunol 2008; 196:60-66.
23.Schlomer JJ,Storey BB,Ciornei RT,McGillis JP. Calcitonin gene-related peptide inhibits early B cell development in vivo. J Leukoc Biol 2007; 81:802-808.
24.Foreman JC. Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int Arch Allergy Appl Immunol 1987; 82:366-371.
25.Springer J, Geppetti P, Fischer A, Groneberg DA. Calcitonin gene-related peptide as inflammatory mediator. Pulm Pharmacol Ther 2003; 16:121-130.
26.Eysselein VE, Reinshagen M, Patel A, Davis W, Nast C, Sternini C. Calcitonin gene-related peptide in inflammatory bowel disease and experimentally induced colitis. Ann N Y Acad Sci 1992; 657:319-327.
27.Kroeger I, Erhardt A, Abt D, Fischer M, Biburger M, Rau T, et al. The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice. J Hepatol 2009; 51:342-353.
28.Tang Y, Feng Y, Wang X. Calcitonin gene-related peptide potentiates LPS-induced IL-6 release from mouse peritoneal macrophages. J Neuroimmunol 1998; 84:207-212.
29.Liu J, Chen M, Wang X. Calcitonin gene-related peptide-enhanced nitric oxide release and inducible NOS activity and mRNA expression in LPS-stimulated mouse peritoneal macrophages. Shock 2001;16:64-69.
30.Yaraee R,Ebtekar M, Ahmadiani A, Sabahi F. Neuropeptides (SP and CGRP) augment pro-inflammatory cytokine production in HSV-infected macrophages. Int Immunopharmacol 2003; 3:1883-1887.
31.Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118.
32.Eskandari F,Webster JI, Sternberg EM. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res Ther 2003; 5:251-265.
33.Jara LJ, Navarro C, Medina G, Vera-Lastra O, Blaanco F. Immune-neuroendocrine interactions and autoimmune diseases. Clin Dev Immunol 2006; 13:109-123.
34.Ghatta S, Nimmagadda D, Calcitonin gene-related peptide: Understanding its role. Indian Jf Pharmacol 2004; 36:277.
35.Nong YH, Titus RG, Ribeiro JM, Remold HG. Peptides encoded by the calcitonin gene inhibit macrophage function. J Immunol 1989; 143:45-49.
36.Cao W, Lee SH, Lu J. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem J 2005; 385:85-93.
37.Prechtel AT, Steinkasserer A.CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch Dermatol Res 2007; 299:59-69.
38.Sansom DM, Manzotti CN, Zheng Y.What's the difference between CD80 and CD86? Trends Immunol 2003; 24:314-319.
39.Perez N, Karumuthil Melethil S, Li R, Praabhakar BS, Holterman MJ, Vasu C. Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1 (+) -adaptive regulatory T cell generation. J Immunol 2008; 180:6566-6576.
40.Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-275.
41.Salek-Ardakani S, Arens R, Flynn R,Sette A, Schoenbereger SP, Croft M. Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells. J Immunol 2009; 182:2909-2918.
42.Suvas S, Singh V, Sahdev S, Vohra H, Agrewala JN. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277:7766-7775.
43.Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
44.Capellino S, Straub RH. Neuroendocrine immune pathways in chronic arthritis. Best Pract Res Clin Rheumatol 2008; 22:285-297.